These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288 [TBL] [Abstract][Full Text] [Related]
24. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630 [TBL] [Abstract][Full Text] [Related]
25. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002 [TBL] [Abstract][Full Text] [Related]
26. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
27. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. Fonseca R; Usmani SZ; Mehra M; Slavcev M; He J; Cote S; Lam A; Ukropec J; Maiese EM; Nair S; Potluri R; Voorhees PM BMC Cancer; 2020 Nov; 20(1):1087. PubMed ID: 33172403 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience. Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321 [TBL] [Abstract][Full Text] [Related]
29. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. van de Donk NW; Lokhorst HM Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099 [TBL] [Abstract][Full Text] [Related]
30. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. Hobeika L; Self SE; Velez JC BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524 [TBL] [Abstract][Full Text] [Related]
31. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406 [TBL] [Abstract][Full Text] [Related]
32. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611 [TBL] [Abstract][Full Text] [Related]
34. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373 [TBL] [Abstract][Full Text] [Related]
35. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272 [TBL] [Abstract][Full Text] [Related]
36. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Wang TF; Ahluwalia R; Fiala MA; Trinkaus KM; Cox DP; Jaenicke M; Moliske CC; Carson KR; Wildes TM; Tomasson MH; Stockerl-Goldstein KE; Vij R Leuk Lymphoma; 2014 Feb; 55(2):337-41. PubMed ID: 23662990 [TBL] [Abstract][Full Text] [Related]